20
Participants
Start Date
October 15, 2018
Primary Completion Date
September 10, 2020
Study Completion Date
May 3, 2021
IFX-1 low dose
Single IV infusions of IFX-1
IFX-1 high dose
Single IV infusions of IFX-1
Placebo
Placebo
Hospital for Special Surgery, New York
Northwell Health, LLC PRIME, New Hyde Park
University of Rochester Medical Center - Strong Memorial Hospital, Rochester
Altoona Center for Clinical Research, P.C., Duncansville
BRCR Medical Center, Inc., Camp Hill
University of Pennsylvania, Philadelphia
Johns Hopkins Bayview Medical Center, Baltimore
UVA University Physicians Charlottesville, Charlottesville
West Virginia University, Morgantown
Low Country Rheumatology, PA, North Charleston
University of Miami, Miami
Science Connections, LLC, Doral
Ohio State University Clinical Trials Management Office, Columbus
Henry Ford Hospital, Detroit
University Of MI Medcl Ctr-RHU, Ann Arbor
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Trinity Medical Group, Minot
Rush University Medical Center, Chicago
Washington University, St Louis
University of Kansas Medical Center Research Institute, Inc., Kansas City
LSU Health Sciences Center Shreveport, Shreveport
Texas Health Resources, Dallas
Texas Research Institute, Fort Worth
Pioneer Research Solutions, Inc., Houston
Adriana Pop Moody Clinic PA, Corpus Christi
Mayo Clinic Scottsdale, Scottsdale
University of New Mexico, Albuquerque
Loma Linda University Clinical Trial Center, Loma Linda
Oregon Health & Science University, Portland
Massachusetts General Hospital, Boston
UNC Kidney Center, UNC-CH Division of Nephrology and Hypertension, Chapel Hill
Rhode Island Hospital, Providence
University of Alberta Hospital, Edmonton
St. Josephs Healthcare, Hamilton
Mount Sinai Hospital, Toronto
CHUM Centre de Recherche, Québec
Centre de Recherche Musculo-Squelettique, Trois-Rivières
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
InflaRx GmbH
INDUSTRY